Glycemia News and Research

RSS

Glycemia or glycæmia is the concentration of glucose in the blood. It is usually expressed in milligrams per deciliter (mg/dl) in the US and other countries. It may also be expressed in millimol per decilitre (mmol/dl) especially in Europe. Both of these are SI units.

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

Baylor Endocrine Center is looking for volunteers to take part in a study to compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes. The project is called the GRADE: Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study.

4 Jun 2013

Investigators use genome analysis to eliminate lifetime drug prescription in two children

Using genome-wide analysis, investigators at the Sainte-Justine University Hospital Research Center and the University of Montreal have potentially eliminated a lifetime drug prescription that two children with a previously unknown type of adrenal insufficiency had been receiving for 14 years.

4 Feb 2013

Toxin-induced insulin resistance combated in mice

French researchers have found that a protein-bound uremic toxin, p-cresyl sulfate, contributes to the development of insulin resistance in mice, providing a new potential therapeutic target for treating chronic kidney disease, they say.

4 Jan 2013

Legume intake reduces heart disease risk in diabetes patients

Diabetes patients who incorporate legumes as part of a low glycemic index diet improve their glycemic control and reduce their risk for coronary heart disease, a study shows.

25 Oct 2012

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received.

27 Sep 2012

George Washington University receives two grants for medical and health research

The George Washington University today announced that it has received two grants totaling nearly $24.5 million dollars, the largest grant allocation the university has received in recent history.

7 Sep 2012

Insulin glargine retards progression of atherosclerosis in high-risk people

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

27 Aug 2012

Diabetes cutoffs don’t quite cut it for South Asians

Individuals of South Asian origin may require closer monitoring for Type 2 diabetes, suggest researchers.

27 Jul 2012

Liraglutide efficacy in Japanese patients “easy” to predict

Liraglutide therapy is an effective alternative to basal-supported oral therapy for some Japanese patients with diabetes, while it is completely ineffective for others, report researchers.

29 Jun 2012

A better understanding of link between glycemic variability and psychological disorders needed

When blood sugar levels in diabetes are poorly controlled, patients tend to have more complications such as depression and other mood disturbances, including anxiety and anger, and a lower overall quality of life.

3 May 2012

DPN similar in prediabetic patients and healthy people

In a reversal of two decades of medical reports, a Mayo Clinic study finds the frequency of nerve damage called diabetic polyneuropathy is similar in prediabetic patients and healthy people. Physicians should seek explanations other than prediabetes for patients who have painful small fiber polyneuropathy, the researchers say.

21 Feb 2012

VIVUS announces results of Qnexa clinical study on cardiometabolic disease

VIVUS, Inc. today announced that results from the SEQUEL study were published in The American Journal of Clinical Nutrition, a peer-reviewed journal with broad, multidisciplinary readership.

9 Dec 2011

Endocrine Society releases clinical practice guideline on continuous glucose monitoring

Patients with diabetes face daily challenges in managing their blood glucose levels, and it has been postulated that patients could benefit from a system providing continuous real-time glucose readings. Today, The Endocrine Society released a clinical practice guideline (CPG) providing recommendations on settings where patients are most likely to benefit from continuous glucose monitoring.

12 Oct 2011

Patients with poorly controlled diabetes may benefit from behavioral, educational interventions

Three randomized controlled trials published Online First today in Archives of Internal Medicine examine the effectiveness of behavioral and educational interventions for patients with poorly controlled diabetes.

11 Oct 2011

Aestus to develop ATx09-002 for treatment of neuropathic pain

Aestus Therapeutics, Inc. and Prosidion Ltd., a wholly owned subsidiary of Astellas Pharma Inc., announced today a license agreement providing Aestus with exclusive, world-wide rights to the Prosidion investigational product PSN-357.

19 Sep 2011

FDA accepts BMY and AstraZeneca's dapagliflozin NDA for review

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for dapagliflozin, an investigational compound for the treatment of adults with type 2 diabetes mellitus.

9 Mar 2011

Avandia label revised as per FDA directive

Following the 2010 FDA directive, pharmaceutical manufacturer Glaxo-SmithKline announced this Monday that they have modified the label for diabetes drug rosiglitazone (Avandia). The new label restricts its use to patients already taking it or to those who have failed other antiglycemic drugs.

8 Feb 2011

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced results from its first Phase 3 trial post hoc analysis in which the higher body mass index (BMI) of the U.S. population relative to the Indian population was a likely key contributor to the more positive effects of D-tagatose in the lowering of HbA1c levels in the U.S. population. Initial results were announced on October 7.

2 Dec 2010

Endocrine Society urges physicians to apply new insights into the role of beta-cells in type 2 diabetes

A new consensus statement published in the September, 2010, issue of The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) finds that the increasing recognition that beta-cell failure occurs much earlier and severely than commonly believed suggests that regular glycemia screening, early identification of patients at metabolic risk and prompt and aggressive intervention deserves greater emphasis.

7 Oct 2010

Arcelis immunotherapy effective in treating autoimmune diseases: Study

Argos Therapeutics today announced that its Arcelis immunotherapy targeted at diabetes demonstrated potential for preventing and treating the disease in non-obese diabetic (NOD) mice, according to a peer-reviewed article published in Molecular Therapy.

4 Aug 2010